GET THE APP

High incidence of cisplatin-induced ototoxicity in pediatrics in | 40008
Pediatrics & Therapeutics

Pediatrics & Therapeutics
Open Access

ISSN: 2161-0665

+44 1478 350008

High incidence of cisplatin-induced ototoxicity in pediatrics in Johannesburg, South Africa


10th World Pediatric Congress

September 28-29, 2017 Dubai, UAE

Mukovhe Chad Phanguphangu

University of Cape Town, South Africa

Scientific Tracks Abstracts: Pediatr Ther

Abstract :

Cisplatin, a highly eff ective chemotherapeutic is associated with high incidences of ototoxicity. Th is cross-sectional retrospective study documents the incidence of cisplatin-induced ototoxicity in pediatrics utilizing data obtained during ototoxicity monitoring of a total of 196 pediatric patients who underwent cisplatin chemotherapy in Johannesburg, South Africa, between January 2015 and December 2016, through conventional audiometry, extended high frequency audiometry and distortion product otoacoustic emissions (DPOAEs). Descriptive and inferential statistics were used for data analysis. 12% of the participants did not develop ototoxicity during treatment. 84% of the participants developed hearing loss of varying degrees during treatment. Additionally, 4% presented with delayed onset of hearing loss detected at 6-weeks post-treatment. While 60% of participants presented with profound SNHL, 12% had a moderate to severe high frequency sensorineural hearing loss and 12% had a SIOP grade 4 ototoxic shift s in the extended high frequency range. Diminished DPOAEs were observed in 92% of the participants. Only 66% of the participants were diagnosed with ototoxicity using conventional audiometry. 3% of the participants presented with mixed hearing loss while 4% had conductive hearing loss. In addition, 78% of the participants presented with chronic cerumen impaction throughout the course of chemotherapy. High pitched tinnitus was reported in 56% of the participants. Th is study highlights a high incidence of cisplatin-induced ototoxicity in pediatrics and thus recommends prospective studies in oto-protection to prevent the negative impacts of cisplatin-induced hearing loss in pediatrics.

Biography :

Mukovhe Chad Phanguphangu has completed his Master’s and Doctoral degrees in Pediatric Audiology from the University of Cape Town, Faculty of Health Sciences. He is the Chief Audiologist at Frere Provincial Hospital and Lectures at Fort Hare University. He has published 11 papers in peer reviewed journals and has presented his research work in 5 international congresses across three continents.

Top